Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A

NCT02600286 | Terminated Phase 2

• 1 other identifier: 6100
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 5

Brief Summary

The disease Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited peripheral neuropathy, for which no treatment has proved its effectiveness. It is autosomal dominant, associated with a duplication of the chromosome 17p11.2 region which leads to overexpression of the gene and the protein-peripheral myelin protein-22 (PMP22), a major component of peripheral myelin. In animals and humans, PMP22 mRNA level of glutathione S-transferase theta 2 and Cathepsin A (markers of oxidative stress), detected in a skin biopsy are markers that may play a role in the prognosis evolution of the disease. Furthermore, several studies have shown that the administration of progesterone increased the expression of PMP22 gene (measured in a skin biopsy) and worsening symptoms. In contrast, anti-progestins reduce the synthesis of PMP22 and improve symptoms in rat CMT1A. The long-term safety of anti-progesterone was evaluated for mifepristone (RU486) ulipristal acetate and (EllaOne®). Few side effects have been reported including a few cases of endometrial hyperplasia reversible upon discontinuation of treatment. With the RU486, rare cases of adrenal androgen and failure have been observed. However, EllaOne® has low antagonistic action on the glucocorticoid receptor and no action on androgen receptors. The investigators therefore believe that it will be well tolerated in humans and will reduce the synthesis of PMP22 and the action of oxidative stress by improving disability of patients.

Conditions

CMT1A

Keywords

Physical medicine and rehabilitation; Neurology

Outcome Measures

Primary Outcomes (1)

• Analysis of the effectiveness of Ellaone. This will be assessed by the production of RNA PMP22 using skin biopsy.

  12 months after treatment with EllaOne

Study Arms (3)

1

EXPERIMENTAL

Arm (1) will be randomised to receive either : * 5 mg/per os of EllaOne every day through 12 months. * 10 mg/per os of EllaOne every day through 12 months. * EllaOne placebo/per os every day through 12 months.

Drug: EllaOne; Drug: EllaOne placebo

2

EXPERIMENTAL

Arm (2) will be randomised to receive either : * 5 mg/per os of EllaOne every day through 12 months. * 10 mg/per os of EllaOne every day through 12 months. * EllaOne placebo/per os every day through 12 months.

Drug: EllaOne; Drug: EllaOne placebo

3

EXPERIMENTAL

Arm (3) will be randomised to receive either : * 5 mg/per os of EllaOne every day through 12 months. * 10 mg/per os of EllaOne every day through 12 months. * EllaOne placebo/per os every day through 12 months.

Drug: EllaOne; Drug: EllaOne placebo

Interventions

EllaOne DRUG

* 5 mg/per os of EllaOne every day through 12 months. * 10 mg/per os of EllaOne every day through 12 months. * EllaOne placebo/per os every day through 12 months.

Also known as: 1: Experimental, 2: Experimental, 3: Experimental

1; 2; 3

EllaOne placebo DRUG

* 5 mg/per os of EllaOne every day through 12 months. * 10 mg/per os of EllaOne every day through 12 months. * EllaOne placebo/per os every day through 12 months.

Also known as: 1: Experimental, 2: Experimental, 3: Experimental

1; 2; 3

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male 18-70 years
• CMT1A proven genetically (17p11.2 duplication)
• symptomatic CMT1A (MRC score \<5 in at least one muscle group)
• Non severe axonal impairment (amplitude of the motor evoked potential on the median nerve and / or ulnar than 50% of normal)
• Subject contacted with a valid phone number
• Subject affiliated to a social security scheme
• Subject has been informed of the results of the medical examination prior

You may not qualify if:

• Another cause of neuropathy: Chronic alcohol intoxication, chemotherapy, diabetes, kidney failure, monoclonal gammopathy, cryoglobulin, B12 deficiency, hepatitis B / C, HIV, Lyme or poliomyelitis
• Liver failure
• Lapp lactase deficiency, malabsoprtion syndrome glucose / galactose
• Support long-term drug interacting with the CYP3A4
• Patients with indication against xylocaine adrenaline
• In the biopsy site: surgery, skin disease or local infection
• Immunosuppression innate or acquired
• Hypersensitivity to the active substance / excipient
• uncontrolled severe asthma
• Treatment with vitamin C or vitamin B3 in the four weeks preceding randomization
• Orthopaedic surgery of the lower limbs in the 6 months prior to randomization or planned
• Against indication xylocaine adrenaline
• Malfunction of the innate or acquired coagulation

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (5)

Service d'Explorations et pathologies neuro- musculaires

Besançon, 25030, France

Location

Département de Neurologie

Dijon, 21079, France

Location

Département de Neurologie

Nancy, 54035, France

Location

Unité de pathologie neuro-musculaire

Paris, 75561, France

Location

Département de Neurologie Centre de Référence des Maladies Neuromusculaires Grand Est (CERNEST) Hôpital de Hautepierre

Strasbourg, 67098, France

Location

Study Officials

• Andoni Echaniz-Laguna, MD

  University Hospital, Strasbourg, France

  STUDY DIRECTOR

• Nicolas Collongues, MD

  University Hospital, Strasbourg, France

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 4, 2015
• First Posted: November 9, 2015
• Study Start: October 23, 2015
• Primary Completion: November 1, 2017
• Study Completion: November 2, 2017
• Last Updated: July 25, 2022

Record last verified: 2022-07

Locations

FR (5)